<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 350 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page349.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=350">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 350 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 350</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=350"><img src="../thumb/350.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.8                                                        2020-04 / 313
       (S4) TABS, 34/21.12/0328      NORPROLAC, Ferring [P/S] &   SANDOSTATIN, Novartis [P/S] &
       894622-005: 200 mg, 3, R1 916,56  Quinagolide.             Octreotide.
       Dosage: Medic.alternat.to surg.terminat.of intrauter.pregn:   Indications: Hyperprolactinaemia (idiopath./ originat. from prolac-  Indications: In adeq.control.acromegaly, acromeg.pts.unwill./
       600 mg per mouth as sngl.dos. Unless abort.has already been compl.  tin-secret.pituit. micro-/macroadenoma).  unfit for surg.or dur.interim per.unt.radiother.becom.full.effect.,
       follow.36-48 hrs.later with a prostagland.analogue (e.g misoprostol)  (S4) TABS. 28/21.12/0528, 0529, 0530, 0531.  gastro-enteropancreatic endocrine tumours assoc. with carcinoid
       Soft. & dilat.of cervix prior to surg.terminat: 600 mg per mouth   829013-008: start.pack(3x25 µg,3x50 µg), R246,96  tumours & VIPomas., emerg.managem.to stop bleed.& to protect
       as sngl.dos.follow.36-48 hrs. later by a surg.terminat.  829021-019: 75 µg, 30, R1 278,02  from re-bleed. due to gastro-oesophag. varices in cirrhot.pts.in as-
       Terminat.in combinat.with prostagland. analogue: 600 mg per   829048-006: 150 µg, 30, R1 770,94  soc. with sclerother.
       mouth as sngl.dos. follow. 36-48 hrs.later by a prostagland.analogue   Dosage: Take at bedt.with food. Titrate indiv:  (S4) INJ. V/34/230, 31,32
       (e.g misoprostol). Rep.prostagland.analogue as necess. If no abort.  Begin treatm.with starter pack tak.25 µg/day for 1st 3 days, follow.by   762342-005: 0,05 mg/ml, 5x1 ml amps, R1 208,74
       within 48 hrs.aft.1  prostagland.admin. follow.alt.proced. D&C not   50 µg/day for furth.3 day. From day 7 onwards recomm.dos.is 75 µg/  762350-008: 0,1 mg/ml, 5x1 ml amps, R2 226,,56
               st
       necess.if compl.abort. has clearly occur.  day. If necess.incr.dly.dos.at interv.not shorter than 1 wk.until optim.  781452-007: 0,2 mg/ml, 5 ml vial, R3 634,38
       Expuls.of dead foetus in utero: 600 mg per mouth as sngl.dos.  respons.obt. Usual maint.dos is 75-150 µg/day. Dly.dos.of 300 µg   Dosage: Sol.to reach room temp.bef.admin.to reduc. loc.discomf.,
                                st
       x2 consec.days. Induc.labour if not start.within 72 hrs.of 1  admin.   or high.reqd.only in &lt; one third of pts. In such cases dly.dos.may be   avoid multiple inj.at short interv. to same site. Pref.to use physiologic.
       Dos.is independ. of body weight.  incr.75-150 µg at interv.not shorter then 4 wks.  saline for dilut.purpos. Infus.not stable in TPN sol.
       Contraindications: Chron.adren.fail., sev. asthma uncontr.by corti-  Contraindications: Safety & effic.in childr.not est., imp.hepat./  Acromegaly: Init. 0,05-0,1 mg SC 8-12 hrly. Adjustm.to be based
       coster.ther., chron.obstruct. airways dis., suspect.ectop.pregn., long-  ren.funct., lactat.  on eff.on lev.of circulat.GH & IGF lev., clinic.sympts, tolerabil. Gen.
       term corticoster. ther., haemorrhag.disords., anticoag. ther., porphyr.,   Side effects: N&V, headache, dizzin., fatig., anorex., other GI dis-  optim. dly.dos.will be 0,3 mg. Do not exceed max.1,5 mg/ day.
       unremov.IUD., ren./hepat.fail.  turbs., insomn., somnol., nas. congest., oed., flush., hypotens., orthos-  Gastro-entero-pancreat.endocrine tumours: Init. 0,05 mg
       Side effects: Heavy bleed.of approx.12 days., uter. pain, uter./UT   tat. hypotens. poss.result.in syncope, ac.psychos. revers. on discont.  SC 1-2xdly, depend.on eff.on levels of circulat.tumour products
       infect., hypotens., malaise, faintn. headache, N&V., skin rashes, di-  Special precautions: Check B/P dur.1st few days of ther.as hy-  on clinic.response & tolerabil. may be grad.incr.to 0,1-0,2 mg
       arrh., vag. sympts., hypertherm.  potens.reacts.poss., since fertility may be restor.adopt contracept.  3xdly. Und. except.circumst.high. dos.may be reqd. Adjust. maint.
       Special precautions: Use only when adeq. emerg. medic.care   meas.where pregn.not desir., psychot.disords., suppress.lactat.,   dos indiv. Discont.ther.in carcin. tumours if no benef.respons.
       is avail., pt.counsell., follow-up visit mandat.to confirm complete   limit.exp. in pregn., monit.closely if pregn.occurs in pres.of pituit.   with.1 wk at max.dos.
       expuls., in the event of fail./interrupt.of meth.pregn.liable to cont.   adenoma where treatm.has been stopped, if sympts. of tumour en-  Bleed.gastro-oesophag.varices: 25 µg/hr by contin. IV infus.x5
       with malformat.risk.theref.pregn.terminat.by other method essent.,   largem.appear re-instit. treatm. /surg.may be appropr., sudd.sleep   days. Very limit.exper.with childr.
       poss.uter.rupt.risk incr.in prev. caes. sect., CV dis., chemoprophylax.  onset episodes partic.with Parkinson’s dis.  (S4) LAR INJ, 33/34/0239, 0240, 0241
       in pres.of prosthet. heart valves/prev.infect.endocardit.epis., smok-  Drug interaction: Dopamine antagonists may reduc.prolactin-low.  Indications: Acromegaly when adeq.control.by SC treatm.with
       ers over 35 yrs., avoid concom.NSAID incl. aspir. until follow-up   eff., alcoh.reduc.toler.  somatostat.analog.or where surg./ radiother.inappropr./ineffect./in
       visit, surg.terminat.to be perform. within 48 hrs.of admin.other-  See also MDR page 334.  interim period until radiother.becomes fully eff., carcinoid tumours
       wise haemorrh. risk incr.                                  with featur.of carcinoid syndr.in whom sympts.are adeq.control.by
                                     PROFINA, Accord [P/S]        SC treatm., VIPomas.
       MYLAN ANASTROZOLE, (Mylan) Xixia.  Finasteride             704532-001: 10 mg, 1 vial & prefill.syr., R18 064,74
       Anastrozole.                  Indications: Tempor.delays furth.hair loss & incr. density in men   704534-001: 20 mg, 1 vial & prefill.syr., R26 771,39
       Indications: Early & advanc.breast Ca in postmenopaus. women.   (betw.18 & 41 yrs) with early androgenet. alopec.  708002-001: 30 mg, 1 vial & prefill.syr., R35 698,84
       Effic.not demonstrat.in oestrog.recept.negat.pts.unless prev.posit.  (S4) TABS, 43/21.12/0055  Dosage: Admin by deep intraglut.inj.alt.sites.
       clinic. respons.to tamoxifen report.  718147-001: 1 mg, 30, R138,38  Acromegaly: Init.20 mg LAR at 4 wk.interv.x3 mnths. Start treatm.
       (S4) TABS. 43/21.12/0590      Dosage: Recomm. 1 tab dly. Usual.necess.for 3 mnths or more   on the 1  day aft.the last dos. of SC octreotide. Adjust.subseq.dos.
                                                                      st
       716573-001: 1 mg, 30, R217,30  bef.incr.hair growth &/furth.hair loss prevent.observ. Contin.use   accord.to GH & IGF conc.& clinic.sympts. Dos.may be incr.to 30 mg
       Dosage: 1 tab.once dly.       recomm.obtain. max.benef. Treatm.withdr.leads to reversabil.of   every 4 wks.if sympts & biochem.paramet not fully control.dur.init.3
       Contraindications: Safety & effic.not est in pre-menopaus.wom-  eff. within 12 mnths.  mnths. If aft.3 mnths. sympts.not full control.on 30 mg dose may be
       en/childr., pregn. & lactat., sev. ren. impairm., mod.to sev.hepat.dis.,   Contraindications: Pregn./poss.pregn., women / paed.use, no   incr. to 40 mg every 4 wks. Dos.may be decr.aft.3 mnth. ther.with
       concom. tamoxifen &/other oestrog.-cont.ther.  studies in elderly men with male pattern hair loss.  20 mg to 10 mg every 4 wks.if ser.conc.& clinic.signs & sympts.con-
       Side effects: Low.circulat.oestrog.lev., hot flush., periph.oed., flush.,   Side effects: S-PSA lev.decr., hypersens.reacts. incl.fac./lip swell.,   sist.normalis.with close monit., In cases where surg./radiother./inap-
       asthen., pelv./back/chest/ bone/ breast pain, anorex., incr.appet.,   palpitat., incr.liv.enzym., skin reacts., impot., decr.libido, decr.ejaculat.  propr/ ineffect/ until radiother.becomes eff.a short test dos. period
       hair thin., rash, sweat., GI disturbs., headache, dizzin., drowsin., car-  vol.& disord., testicul.pain, breast tendern./enlargem.  of SC Sandostatin is recomm.to assess respons. & system. tolerabil.
       pal.tunnel syndr., depress., dyspn., cough, pharyngit., hypertens., vag.  Special precautions: Pregn./potent.pregn. women not to han-
       dryn./bleed., weight gain, hypercholesterolaem., somnol., insomn.,   dle brok./crush.tabs.due to risk to male foetus, abnorm.to ext.  prior to init.LAR ther. as above.
                                                                  Carcinoid tumours:For pts.adeq.control.on SC admin init.treatm.
       nervous., paraesthes., anx., confus., anaem., leucopen.with/without
       infect., thrombo-embol./ phlebit., erythema multiforme, Stev.John.   genitil.of male foetus when admin.dur.pregn., pres.in semen: men   at 20 mg LAR at 4 wk.interv. Contin.treatm.of SC Sandostatin at the
                                     to use condom/avoid sex.female partn., 50% decr. in S-PSA in
                                                                  prev. effect. dos.x2 wks.aft.1  LAR inj. In pts.not prev. treat. with SC
                                                                              st
       syndr., allerg./skin reacts., angioed., anaphylax., bronchit., sinusit.,
       rhinit., flu-like syndr, myalg., arthralg., joint pain/stiffn., bone fract.  older pts.with BPH.  Sandostatin start admin.SC Sandostatin at dos.of 0,1 mg 3xdly x2
                                                                  wks to assess respons.& system.tolerabil.bef.admin.LAR as describ.
       Special precautions: Poss.bone miner.dens. reduct. with incr.  PROPECIA, MSD [P/S]  above. If aft. 3 mnths.sympts.only partially controll.incr.dos. to 30 mg
       fract.risk, furth.eval.if vag. bleed. persists, biochem.confirmat.of   Finasteride.  every 4 wks. For days when sympts of carcinoid tumours incr. dur.
       menopause if in doubt., lact.intol.pts.  Indications: Temp.delays further hair loss & incr.hair dens.in the   treatm.admin.addit.SC Sandostat.at dos.prior to switch.to LAR. This
       Drug interactions: Tamoxifen &/other oestrog. contain. ther.would   vertex & anterior mid scalp area in men betw.18 & 41 yrs.with early   st
       dimin.pharmac.act.            signs of androgenet.alopec.  may occur main.in 1  2 mnths.treatm.
                                                                  Side effects: Very common: Diarrh., abdom. pain, naus., flatul.,
       NEOPHEDAN, (Aspen Pharmacare: Pharma) Pharmacare  (S4) TABS. 32/21.12/0303.  headache, cholelithias., hyperglycaem., constipat., dizzin., loc.pain.,
       Tamoxifen citr.equiv.to tamoxifen  852570-007: 1 mg, 28, R352,28  bil. sludge, thyroid dysfunct., loose stools, imp.gluc tol., vomit., as-
       Indications: Palliative advanced Ca-breast in post-menopaus.  Dosage: 1 mg dly.with/without food. Use for 3 mnths.or more   then, hypoglycaem. Common: Anorex., bradycard., dyspn., dys-
       women.                        necess.bef.incr.hair growth &/prev.of further hair loss observ. Con-  peps., vomit., abdom. bloat., steatorrh., faeces.discolourat., chol-
       (S4) TABS. S/26/379, 380.     tin.use recomm.for max benef.  ecystit., prurit., rash, alopec. Uncommon: Dehydrat., tachycard.,
       782157-009: 10 mg, 30, R112,40  Contraindications: Pregn./poss.pregn., lactat., women/childr.,   Post market: hypersens. incl. anaphylax., urticar., ac.pancreatit.,
       782165-001: 20 mg, 30, R152,99  safety & effic.in elderly not est.  ac.hepatit. without cholestas., cholestat. hepatit./-jaund., choles-
       For further details refer to manufact.prod.lit.  Side effects: Uncommon: Erect.dysfunct., decr. ejaculat.vol., decr.  tas., jaund., dysrhythm.
                                     libido, Post market: Rash, hypersens. reacts.incl.prurit., urticar.&
       NOLVADEX-D, AstraZeneca       swell.of lips & face, depress., contin.decr.libido& sex.dysfunct.,   Warnings and special precautions: Monit.all pts for tumour
                                                                  expans.caref.& seek alt.ther.if evid., potent. fertility restorat.in fem.
       Tamoxifen                     breast tendern./ enlargem., testicul.pain, haematosperm., male in-  acromegal.pts theref. adeq. contracept.advis., monit.thyroid funct.,
       Indications: Breast Ca.       fertility/poor semin.quality which improv.aft.discont.  poss.dos.adjustm.of beta-block./Ca chann.block.& agents control.
       (S4) TABS, S/21.12/41.        Warnings and special precautions: Male pts. to report any   fuid & electrol.bal., 6 mnthly. ultrasonagraphy for gallston.dur.ther.,
       747432-007: 20 mg, 30, R659,53  changes in breast tiss./-lumps/ gynaecomast/nipple discharge,   diab.mellit.requir.insulin may requir.dos.adjustm., gluc.tol./gluc.bld
       Dosage: Adults incl elderly: 20-40 mg in div.dos 2xdly or as sngl.  male breast Ca hist., male infertility &/poor semin.quality re-  lev.& antidiab. monit.recomm., poss.alter.absorpt.of diet.fats, vit.
       dly.dos.                      port., not effect.in postmenopaus.women with androgenet. alo-  B 12 deprivat.hist., poss.decr.metabol.with concom. admin.of meds.
       Contraindications: Pregn.,    pec., withdr.of treatm.leads to reversib.of eff.with.12 mnths., 50   metabol.by cytochrome P-450 & CYP3A4, use in pregn.& lactat.
       Side effects: Pancreatit., interstit.pneumonit, hot flush., menstr.  % decr.ser. prostate specif.antigen in old.men with BPH, pregn./   limit.with safety in pregn.not est., excret.in breast milk in anim.
       suppress., ischaem.cerebrovasc. events, thrombolyt.events incl.DVT/  potent.pregn.women not to handle brok./ crush.tabs.due to risk to   stud., limit exper.in childr., safety of LAR use in childr not est., no
       pulm.embol., vag. bleed.& discharg., prurit.vulv., endometr. chang.   male foetus, lact.intol.  data avail.in imp.hepat.funct./in elderly, safety & effic. in childr.
       incl.hyperplas.& polyps, GI effs., skin reacts. incl.Stev.John.syndr.,   not est., GI S/E may resemble ac.intestin. obstruct., relationship
       headache, lightheadedn., tumour flare, fluid retent., fatig., weight   PROSCAR 5, MSD [P/S]  of ECG changes to Sandostatin not est.as many pts.have underly.
       gain, leg cramps, uter.fibroids, endometr. Ca, hypersens.reacts., bld.  Finasteride.  card.dis., cholelithias.-induc. pancreatit.with prolong.use, depress.
       dyscras., vis.disturbs. incl. corn.chang./cataracts/retinopathy, uter.   Indications: Benign prostat.hyperplas.(BPH).  vit.B12 lev., not an antitumour ther.& is not curat.in these pts., use
       sarcoma, endometrios., ovar.cysts, pancreatit., liv. abnorm., choles-  (S4) TABS. 27/21.12/0069.  und. compel.circumst.in pregn.pts., assess GH & IFG 1 6 mnthly.in
       tas., hypercalcaem., alopec.  793736-005: 5 mg, 28, R779,04  acromegaly pts.on stable dos., liv. cirrhos., sudd. escape from symp-
       Special precautions: Caref.exam.in pre-menopaus. pts.bef.init.  Dosage: 5 mg dly.  tomat.control of gastro-enteropancreat. endocr.tumours may occur
       ther.to excl.pregn., concom. coumar. anticoags.incr. anticoag.eff.   Contraindications: Pregn./poss.pregn., use in paed pts./women,   with rapid recurr.of sev.sympts., GI side effs.may be reduc.by avoid
       with poss. bleed. risk theref.reduct.of anticoag.dos.& caref. pt.   safety in lactat.not est.  admin.around meal times.
       monit. recomm., incr.incid.endometr.Ca & uter. sarcoma, abnorm.  Side effects: Common: Decr.ejaculat.vol., impot., decr.libido, Post   Drug interactions: Reduc.intestin.absorpt.of cyclospor. & delays
       gynae.sympt.esp.vag.bleed.to be investigat., occur.of second.prim.  market: Male breast Ca, rash, hypersens.reacts.incl.prurit., urticar.&   that of cimetidine, bioavailabil. of bromocriptine incr.
       tumours, high dos. incr ALA-synthase in animal studies although   swell.of lips & face, depress., contin.decr.libido& sex.dysfunct.,   See also MDR page 568.
       no reports of porphyr., attacks have been assoc.in man, spontan.  breast tendern./ enlargem., testicul.pain, haematosperm., male in-
       abort./foet.deaths./birth defects report. if used dur.pregn., avoid   fertility/poor semin.quality which improv.aft.discont.  SENSIPAR, Amgen &
       pregn.while on ther. /within 2 mnths.of cessat., reduc.dos.if S/E   Warnings and special precautions: Monit.for obstruct. uropathy   Cinacalcet
       sev. & stop treatm.if no respons., safety in lactat. not est., safety   & prost.Ca, poss.abnormalit.to extern.genital.of male foetus., 50 %   Indications: Second.hyperparathyroid.in end-stage ren.dis.pts.
       & effic.in childr.not est.    decr.ser. prostate specif.antigen in BPH & doesn’t rule out prostate   on maint.dialys.ther., as part of therapeut.regim.incl.phosph.bind.
       Drug interactions: Incr.risk of thrombo-embol. events in combi-  Ca pres., eval.pts with sustain.incr.in S-PSA lev.careful., expos.to   and/or Vit.D sterols as appropr., hypercalcaem.reduct.in parathy-
       nat.with cytotox.             crush/brok.tabs.by pregn./poss.pregn.women  roid Carcinoma</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page349.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>
             </td>
             <td width="35%"><a href="page351.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page351.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
